Citation: | GU Nian, SHENG Xinyi, QIN Chao, CHEN Jintuo, XU Siyuan, YIN Lifang. Preparation and gastrointestinal absorption kinetics of tacrolimus solid dispersion[J]. Journal of China Pharmaceutical University, 2016, 47(6): 694-701. DOI: 10.11665/j.issn.1000-5048.20160611 |
[1] |
Liu F, Wei JF, Meng L, et al. New development in macrolide immunosuppressant[J].Chin New Drugs J(中国新药杂志),2014,22(1):61-66.
|
[2] |
Liu YS,Gao S,Ke X,et al.Recent research advances in solid dispersions of poorly soluble drugs[J].Prog Pharm Sci(药学进展),2013,37(4):166-173.
|
[3] |
Yan F,Ke X,Ping QN,et al.Preparation of baicalein solid dispersions and oral bioavailability in rats[J].J China Pharm Univ(中国药科大学学报),2008,39(5):406-411.
|
[4] |
Zhang Q, Zhang MX, Zhang J, et al. Studies on the intestinal absorption kinetics of tacrolimus in rats[J].Chin Hosp Pharm J(中国医院药学杂志),2010,30(8):639-642.
|
[5] |
Veloxis Pharma Inc.Modified release tacrolimus compositions:CN,1859910A[P].2006-11-08[2016-03-11] .
|
[6] |
Arik D, Brady T, Gordon L, et al. Segmental-dependent membrane permeability along the intestine following oral drug administration:evaluation of a triple single-pass intestinal perfusion(TSPIP)approach in the rat[J].Eur J Pharm Sci,2009,36:320-329.
|
[7] |
Ying J,Lyu Y,Du GH.New development in amorphous drug[J].Acta Pharm Sin(药学学报),2009,44(5):443-448.
|
[8] |
Astellas Pharma Inc.Tacrolimus sustained release pharmaceutical composition:EP,2119442A[P].2009-11-18[2016-03-11] .
|
[1] | YAO Lei, QU Linlin, FAN Daidi. Effects of rare ginsenoside on idiopathic pulmonary fibrosis[J]. Journal of China Pharmaceutical University, 2023, 54(5): 607-613. DOI: 10.11665/j.issn.1000-5048.2023042002 |
[2] | HUANG Zhicheng, YE Liu, DU Yu, GU Hongfeng, GAO Fanyun, ZHU Qihua, XU Yungen. Design, synthesis and biological evaluation of PARP-1/PI3K dual-target inhibitors[J]. Journal of China Pharmaceutical University, 2023, 54(4): 450-460. DOI: 10.11665/j.issn.1000-5048.2023050301 |
[3] | WANG Yanmei, YANG Lei, XIN Xiaofei, YIN Lifang. Combination therapy and drug delivery strategies for treatment of non-alcoholic fatty liver disease[J]. Journal of China Pharmaceutical University, 2022, 53(4): 423-432. DOI: 10.11665/j.issn.1000-5048.20220405 |
[4] | LI Xiaoshi, WU Xunxun, ZHENG Zuguo, YANG Hua, LI Ping. Advances of long noncoding RNAs in myocardial fibrosis[J]. Journal of China Pharmaceutical University, 2020, 51(6): 646-654. DOI: 10.11665/j.issn.1000-5048.20200602 |
[5] | KE Ke, JIANG Wenli, WANG Yu, ZHU Jingyu, JIN Jian. Study on the bioactivity against hematologic malignancies and theoretical binding mechanism of a novel PI3K inhibitor JN-65[J]. Journal of China Pharmaceutical University, 2019, 50(4): 410-416. DOI: 10.11665/j.issn.1000-5048.20190405 |
[6] | CAI Yanfei, WAN Aini, CHEN Yun, JIN Jian. Anti-liver fibrosis activities of the extracellular domain of transforming growth factor beta type II receptor fusion protein in vivo[J]. Journal of China Pharmaceutical University, 2019, 50(2): 246-252. DOI: 10.11665/j.issn.1000-5048.20190217 |
[7] | FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302 |
[8] | WAN Aini, XU Dongsheng, CAI Yanfei, CHEN Yun, JIN Jian, LI Huazhong. Anti-liver fibrosis activities of human insulin-like growth factor-1 in vitro[J]. Journal of China Pharmaceutical University, 2017, 48(4): 476-482. DOI: 10.11665/j.issn.1000-5048.20170413 |
[9] | DAI Li, ZHANG Lu, JI Hui, KONG Xiang-wen. Therapeutic effects of ZK14,a novel nitric oxide donating biphenyldicarboxylate derivative,on hepatic fibrosis in rats[J]. Journal of China Pharmaceutical University, 2009, 40(3): 254-257. |
[10] | Danshen Inhibiting Isoproterenol Induced Cardiac Hypertrophy and Fibrosis in Mice and its Mechanisms[J]. Journal of China Pharmaceutical University, 2003, (6): 84-87. |